This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Phase 3, study of ATEZOLIZUMAB(ANTI-PD-L1 Antibody)
Hi,
My brother was diagnosed in July of 2016, with a gleason score 9 with bone mets. He was given 6 rounds of chemo along with ADT(lupron). His PSA at the time of diagnoses was 84, came down to .5 after chemo back in Nov 2016.
He has been on zytiga since January of this year, and his PSA has been rising slowly and it is now 1.6. His latest CT and PET scan was clear and his overall health is good, except for a persistant pain in back, manageable only with high doses of advil.
His Onco wants to put him on a phase 3 trail of ATEZOLIZUMAB(ANTI-PD-L1 Antibody) and switch him over from zytiga to xtandi.
Has anyone heard of this trail or know of anyone who has tried it?
Would appriciate comments from the group.
